JPHC CE: Pharmacological Management of Pediatric Clostridioides difficile Infection: Clarifying the Controversies
1.25 contact hour of which 1.25 contain pharmacology content. This continuing education activity is offered free to NAPNAP Members. For non- members, this continuing education activity rate is $10.
You must be logged in to use your NAPNAP Member ID# and Password to be recognized as a Member of NAPNAP. If you are a current member of NAPNAP, and you are being asked to purchase this activity, please contact the NAPNAP National Office at (877) 662-7627 to request assistance prior to entering any information.
Participants are forbidden to reproduce, republish, redistribute, or resell this course in any other form. For copyright-related questions, please email your question to: email@example.com
Copyright © 2021 by the National Association of Pediatric Nurse Practitioners. Published by Elsevier Inc. All rights reserved.
This continuing education activity is administered by the National Association of Pediatric Nurse Practitioners (NAPNAP) as an Agency providing continuing education credit. Individuals who complete this program and earn a 70% or higher score on the post test will be awarded 1.25 NAPNAP contact hours of which 1.25 is pharmacology content.
Keywords: Pediatric, pharmacotherapy, Clostridioides difficile-infection
Pediatric-focused advanced practice registered nurses
1 Describe the prevalence, pathogenesis, and diagnosis of Clostridioides difficile infection (CDI) in pediatric patients.
2 Identify modifiable and nonmodifiable risk factors forCDI in pediatric patients.
3 Recognize available medications and therapies used in the treatment and management of CDI infection in pediatric patients.
4 Evaluate new evidence supporting the safety and efficacy of various pharmacological agents used in the management of pediatric CDI.
Mackenzie N. DeVine, Pediatric Clinical Pharmacist, Department of Pharmacy, Children’s Hospital Colorado, Aurora, CO.
Christine E. MacBrayne, Antimicrobial Stewardship and Infectious Diseases Clinical Pharmacist Specialist, Department of Pharmacy, Children’s Hospital Colorado, Aurora, CO.
Jason Child, HIV/Infectious Diseases and Antimicrobial Stewardship Clinical Specialist, Children’s Hospital Colorado, Aurora, CO.
Allison B. Blackmer, Director, Clinical Practi ce, Quality and Advocacy; American Society for Parenteral and Enteral Nutrition and Adjunct Associate Professor of Pharmacy; University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO.
Conflicts of interest: None to report.
Jason Child and Allison B. Blackmer performed consultative services for Wolters Kluwer, Pediatric and Neonatal Lexi-Drugs in 2020. In addition, Allison B. Blackmer serves as a member of the Drug Utilization Review Board for Colorado Department of Health Care Policy and Financing.
Correspondence: Mackenzie N. DeVine, PharmD, BCPPS,
Department of Pharmacy, Children's Hospital Colorado, 13123 E
16th Ave., Box 375, Aurora, CO;
- 1.25 Contact hours